Activatable Antibody Compositions with Clipped-Variant Removal

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Monoclonal antibody compositions face challenges with product aggregation, leading to lower yields and potential safety issues due to the formation of clipped variants that indiscriminately bind to healthy cells, causing dose-dependent toxicities and reducing the efficacy of therapeutic antibodies.

Innovation Solution

A process involving hydrophobic chromatography is used to separate intact activatable antibodies from clipped variants, achieving high purity and yield by exploiting differences in hydrophobic interactions, resulting in a composition with minimal clipped impurity and other contaminants.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If monoclonal antibody products are manufactured using conventional processes, then significant advances in manufacturing processes have been achieved, but product aggregation occurs resulting in lower yields and safety issues

Engineering Contradiction:

Improvemanufacturing processVSAvoidproduct aggregation

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent extracts and removes clipped variants and aggregates from the antibody composition through chromatography purification processes. The method specifically targets and separates these harmful aggregated forms from the intact activatable antibodies, thereby eliminating the safety issues and yield losses associated with product aggregation while maintaining the benefits of conventional manufacturing.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs chromatography conditions with specific pH ranges (6.0-8.0) and ionic strength parameters to optimize the separation of intact antibodies from clipped variants. By carefully controlling these physical-chemical parameters during purification, the method achieves high recovery of monomeric antibody while removing aggregated species, thus resolving the contradiction between manufacturing ease and product reliability.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If structural changes are made to improve safety and efficacy of antibody-based therapeutics, then safety and efficacy are improved in certain cases, but additional challenges are introduced in manufacturing purified antibody-based therapeutics

Engineering Contradiction:

Improvesafety and efficacyVSAvoidmanufacturing purified antibody-based therapeutics

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent incorporates a masking moiety into the activatable antibody structure beforehand, which prevents premature activation and reduces the formation of clipped variants during manufacturing. This preliminary structural modification ensures that the antibody remains stable and non-toxic throughout the purification process, thereby improving both safety and manufacturability simultaneously.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The masking moiety acts as an intermediary element that temporarily blocks the antigen-binding domain, preventing unwanted interactions during manufacturing. This intermediary structure allows the antibody to be handled and purified without causing the safety issues associated with activated forms, while still allowing for controlled activation later in the therapeutic process.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If clipped variants are present in the composition, then they are produced during manufacturing, but they indiscriminately bind to healthy cells causing dose-dependent toxicities and reducing therapeutic efficacy

Engineering Contradiction:

Improvemanufacturing outputVSAvoidoff-target toxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the potentially harmful clipped variants into a benefit by using their presence as an indicator for optimized purification. The method is specifically designed to recognize and remove these variants through chromatography, transforming what would be a toxic contaminant into a target for elimination, thereby ensuring the final product has minimal off-target toxicity while maintaining high productivity.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent employs analytical methods to detect and quantify clipped variants in the composition, using this information as feedback to optimize the purification process. By monitoring the levels of clipped variants and adjusting chromatography conditions accordingly, the method ensures thorough removal of toxic species while maintaining high yields of intact therapeutic antibodies.

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process effectively removes clipped variants and other impurities, enhancing the safety and efficacy of monoclonal antibody therapies by maintaining high levels of intact, non-aggregated activatable antibodies, thereby reducing off-target toxicity and increasing therapeutic effectiveness.

Implementation Method 1

Methodology Applied

Scientific EffectHydrophobic interaction: Hydrophobe

Data Source

PatentUS12428470B2Compositions containing activatable antibodies

Publication Date: 2025.09.30 CYTOMX THERAPEUTICS INC

AI summary

The invention provides a composition including an intact activatable antibody and a clipped variant thereof, methods of separating clipped variants of intact activatable antibodies from intact activatable antibodies and related methods including methods for determining or monitoring a relative percentage of an activatable antibody and a clipped variant thereof during a composition production process.